Skip to main content
SpringerLink
Log in

Antidementiva

  • Chapter
Handbuch der Psychopharmakotherapie

  • 2574 Accesses

Auszug

Zu Beginn sollen folgende Begriffe geklärt werden, die oft unpräzise oder in falschem Zusammenhang gebraucht werden: Neuroprotektiva, Nootropika und Antidementiva (⊡ Box).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Adamik B, Monthe C, Bender H (2006) Intravenous immunoglobuline (IVIG) maintains cognition over 18 months in patients with Alzheimer’s disease. Alzheimers Dementia 2(3 Suppl. 1): 62–63

    Article  Google Scholar 

  • Aisen PS, Davis KL, Berg JD et al (2000) A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 54(3): 588–593

    PubMed  CAS  Google Scholar 

  • Aisen PS, Schafer KA, Grundman M et al; Alzheimer’s Disease Cooperative Study (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289: 2819–2826

    Article  PubMed  CAS  Google Scholar 

  • Akiyama H, Barger S, Barnum S et al (2000) Inflammation in Alzheimer’s disease. Neurobiol Aging 21: 383–421

    Article  PubMed  CAS  Google Scholar 

  • Anand R, Hartman R, Sohn H, Danyluk J, Graham SM (2003) Impact of study design and patient population on outcomes from cholinesterase inhibitor trials. Am J Geriatr Psychiatry 11: 160–168

    Article  PubMed  Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2001) Empfehlungen zur Therapie der Demenz. Arzneiverordnungen in der Praxis; Sonderheft Therapleempfehlungen, 2. Aufl. Januar 4: 1–12

    Google Scholar 

  • Bal Dit Sollier C, Caplain H, Drouet L (2003) No alteration in platelet function or coagulation induced by EGb 761 in a controlled study. Clin Lab Haematol 25: 251–253

    Article  PubMed  CAS  Google Scholar 

  • Bastianetto S, Quirion R (2002) EGb 761 is a neuroprotective agent against beta-amyloid toxicity. Cell Mol Biol (Noisy-le-grand) 48(6): 693–697

    CAS  Google Scholar 

  • Behl C (2005) Oxidative stress in Alzheimer’s disease: implications for prevention and therapy. Subcell Biochem 38: 65–78

    PubMed  CAS  Google Scholar 

  • Behl C, Holsboer F (1999) The female sex hormone estrogen as a neuroprotectant. Trends Pharmacol Sci 20: 441–444

    Article  PubMed  CAS  Google Scholar 

  • Bentue-Ferrer D, Tribut O, Polard E, Allain H (2003) Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 17: 947–963

    Article  PubMed  CAS  Google Scholar 

  • Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, Kuller L, for the Cardiovascular Health Study Collaborative Research Group (2005) Statins and cognitive function in the elderly. Neurology 65: 1388–1394

    Article  PubMed  CAS  Google Scholar 

  • Bhat RV, Budd-Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89(6): 1313–1317

    Article  PubMed  CAS  Google Scholar 

  • Bickel U, Thomsen T, Fischer JP, Weber W, Kewitz H (1991) Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice. Neuropharmacology 30: 447–454

    Article  PubMed  CAS  Google Scholar 

  • Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 1: CD005593

    PubMed  Google Scholar 

  • Boothby LA, Doering PL (2005) Vitamin C and vitamin E for Alzheimer’s disease. Ann Pharmacother 39(12): 2073–2080

    Article  PubMed  CAS  Google Scholar 

  • Canevari, L, Clark JB (2007) Alzheimer’s disease and cholesterol: a fat connection. Neurochem Res 32: 739–750

    Article  PubMed  CAS  Google Scholar 

  • Carlson MC, Zandi PP, Plassman BL et al (2001) Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study. Neurology 57: 2210–2216

    PubMed  CAS  Google Scholar 

  • Costa MM, Reus VI, Wolkowitz OM, Manfredi F, Lieberman M (1999) Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiatry 46: 182–188

    Article  PubMed  CAS  Google Scholar 

  • Courtney C, Farrell D, Gray R et al; AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trail. Lancet 363: 2105–2115

    Article  PubMed  CAS  Google Scholar 

  • Davis JM, Chen N, Glick ID (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564

    Article  PubMed  CAS  Google Scholar 

  • De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S, Lawlor BA (1999) A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53: 946–955

    PubMed  Google Scholar 

  • Dunn N, Holmes C, Mullee M (2005) Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 19(1): 20–22

    Article  PubMed  CAS  Google Scholar 

  • Eckert A, Keil U, Scherping I, Hauptmann S, Müller WE (2005) Stabilization of mitochondrial membrane potential and improvement of neuronal energy metabolism by Ginkgo biloba extract Egb 761. Ann NY Acad Sci 1056: 474–485

    Article  PubMed  Google Scholar 

  • Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351: 2509–2518

    Article  PubMed  CAS  Google Scholar 

  • Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM (2002) Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287: 3223–3229

    Article  PubMed  CAS  Google Scholar 

  • Enz A, Boddeke H, Gray J, Spiegel R (1991) Pharmacologic and clinicopharmacologic properties of SDZENA713, a centrally selective acetylcholinesterase inhibitor. Ann NY Acad Sci 640: 272–275

    PubMed  CAS  Google Scholar 

  • Etminan M, Gill S, Samii A (2003) Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer’s disease: systematic review and metaanalysis of observational studies. Br Med J 327: 128

    Article  CAS  Google Scholar 

  • Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group (2001) A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 57: 613–620

    PubMed  CAS  Google Scholar 

  • Feldman HH, Ferris S, Winblad B et al (2007) Effects of rivastigmine on delay to diagnosis of Alzheimer’s disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 6: 501–512

    Article  PubMed  CAS  Google Scholar 

  • Frampton M, Harvey RJ, Kirchner V (2003) Propentofylline for dementia. Cochrane Database Syst Rev 2: CD002853

    PubMed  Google Scholar 

  • Gabelli C (2003) Rivastigmine: an update on therapeutic efficacy in Alzheimer’s disease and other conditions. Curr Med Res Opin 19: 69–82

    Article  PubMed  CAS  Google Scholar 

  • Garino C, Tomita T, Pietrancosta N et al (2006) Naphthyl and coumarinyl biarylpiperazine derivates as highly potent human betasecretase inhibitors. Design, synthesis, and enzymatic BACE-1 and cell assays. J Med Chem 49(14): 4275–4285

    Article  PubMed  CAS  Google Scholar 

  • Geerts H, Grossberg GT (2006) Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer’s disease. J Clin Pharmacol 46: 8S–16S

    Article  PubMed  CAS  Google Scholar 

  • Grossberg GT, Edwards KR, Zhao Q (2006) Rationale for combination with galantamine and memantine in Alzheimer’s disease. J Clin Pharmacol 46: 17S–26S

    Article  PubMed  CAS  Google Scholar 

  • Hock C, Konietzko U, Streffer JR et al (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer’s disease. Neuron 38(4): 547–554

    Article  PubMed  CAS  Google Scholar 

  • Hogervorst E, Yaffe K, Richards M, Huppert F (2002) Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev 3: CD003799

    PubMed  Google Scholar 

  • Hoyer S, Riederer P (2007) Alzheimer disease — no target for statin treatment. Neurochem Res 32: 695–706

    Article  PubMed  CAS  Google Scholar 

  • Hoyer S, Lannert H, Noldner M, Chatterjee SS (1999) Damaged neuronal energy metabolism and behavior are improved by Ginkgo biloba extract (EGb761). J Neural Transm 106(11–12): 1171–1188

    Article  PubMed  CAS  Google Scholar 

  • Jack CR, Petersen RC, Grundman M et al;Members of the Alzheimer’s disease colabarative study (ADCS) (2007) Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging (Epub ahead of print)

    Google Scholar 

  • Jann MW, Shirley KL, Small GW (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41(10): 719–739

    Article  PubMed  CAS  Google Scholar 

  • Klegeris A, McGeer PL (2005) Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res 2(3): 355–365

    Article  PubMed  CAS  Google Scholar 

  • Kornhuber J (Hrsg), Knöpfel S (2001) Blickpunkt Memantine, 4. Aufl. Aesopus-Verlag, Linkenheim-Hochstetten

    Google Scholar 

  • Li L, Cao D, Kim H, Lester R, Fukuchi K (2006) Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 60: 729–739

    Article  PubMed  CAS  Google Scholar 

  • Lichtenthaler SF, Haass C (2004) Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidgenesis in an Alzheimer disease mouse model. J Clin Invest 113 (10): 1384–1387

    Article  PubMed  CAS  Google Scholar 

  • Livingston G, Katona C (2004) The place of memantine in the treatment of Alzheimer’s disease: a number needed to treat analysis. Int J Geriatr Psychiatry 19: 919–925

    Article  PubMed  Google Scholar 

  • Lopez-Arrieta JM, Birks J (2001) Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Syst Rev 3: CD000147

    Google Scholar 

  • Loy R, Tariot PN (2002) Neuroprotective properties of valproate: potential benefit for AD and tauopathies. Mol Neurosci 19: 303–307

    CAS  Google Scholar 

  • Loy C, Schneider L (2006) Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev 1: CD001747

    PubMed  Google Scholar 

  • Maier M, Seabrook TJ, Lemere CA (2005) Developing novel immunogens for an effective, safe Alzheimer’s disease vaccine. Neurodegener Dis 2(5): 267–272

    Article  PubMed  CAS  Google Scholar 

  • Master CL, Cappal R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for Alzheimer’s disease: Implications for neuroimaging and therapeutics. J Neurochem 97: 1700–1725

    Article  CAS  Google Scholar 

  • Matsuka Y, Saito M, La Francois J et al (2003) Novel therapeutic approach for the treatment of Alzheimer’s disease by periphereal administration of agents with an affinity to beta-amyloid. J Neurosci 23(1): 29–33

    Google Scholar 

  • Matsuka Y, Shao L, Debnath M et al (2005) An beta sequestration approach using non-antibody Abeta binding agents. Curr Alzheimer Res 2(2): 265–268

    Article  Google Scholar 

  • McKeith I, Mintzer J, Aarsland D et al and on behalf of the International Psychogeriatric Association Expert Meeting on DLB (2004) Dementia with Lewy bodies. Lancet Neurol 3: 19–28

    Article  PubMed  Google Scholar 

  • McShane R, Areosa Sastre A, Minakaran N (2006) Memantine for dementia. Cochrane Database Syst Rev 2: CD003154

    PubMed  Google Scholar 

  • Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1–40). Brain Res 958: 210–221

    Article  PubMed  CAS  Google Scholar 

  • Mohs RC, Doody RS, Morris JC, Leni JR, Rogers SL, Perdomo CA, Pratt RD; »312« Study Group (2001) A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481–488

    PubMed  CAS  Google Scholar 

  • Mulnard RA, Cotman CW, Kawas C et al (2000) Estrogen replacement therapy for treatment of mild to moderate Alzheimer’s disease: a randomized controlled trial. Alzheimer’s disease collaborative study. JAMA 283(8): 1007–1015

    Article  PubMed  CAS  Google Scholar 

  • Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nature Med 9(4): 448–452

    Article  PubMed  CAS  Google Scholar 

  • Nink K, Schröder H (2001) Arzneimittelverordnungen nach Altersgruppen 2000. Wissenschaftliches Institut der AOK, Bonn

    Google Scholar 

  • Nunomura A, Castellani RJ, Zhu X, Moreira PI, Perry G, Smith MA (2006) Involvement of oxidative stress in Alzheimer disease. J Neuropath Exp Neurol 65(7): 631–641

    Article  PubMed  CAS  Google Scholar 

  • Ohnishi A, Mihara M, Kamakura H et al (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 33: 1086–1091

    PubMed  CAS  Google Scholar 

  • Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S (2006) Memantine treatmentin mild to moderate Alzheimer disease: a 24-week randomized controlled trial. Am J Geriatr Psychiatry 8: 704–715

    Google Scholar 

  • Petersen RC, Thomas RG, Grundman M et al (2005) Vitamin E and donepezil for treatment of mild cognitive impairment. N Engl J Med 352(23): 2379–2388

    Article  PubMed  CAS  Google Scholar 

  • Raskind MA, Peskind ER, Wessel T, Yuan W (2000) Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54: 2261–2268

    PubMed  CAS  Google Scholar 

  • Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ; Memantine Study Group (2003) Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348: 1333–1341

    Article  PubMed  CAS  Google Scholar 

  • Riekse RG, Leverenz JB, McCormick W et al (2004) Effect of vascular lesions on cognition in Alzheimer’s disease: a community-based study. J Am Geriatr Soc 52: 1442–1448

    Article  PubMed  Google Scholar 

  • Riepe MW, Frölich L, Gertz H-J et al (2005) Evidenzbasierte medikamentöse Therapie der Alzheimer-Erkrankung. Dtsch Ärztebl 102(51–52): A3587–A2593

    Google Scholar 

  • Riepe MW, Adler G, Ibach B, Weinkauf B, Gunay I, Tracik F (2006) Adding memantine to rivastigmine theapy in patients with mild-to-moderate Alzheimer’s disease: results of a 12-week, open-label pilot study. Prim Care Companion J Clin Psychiatry 8: 258–263

    PubMed  Google Scholar 

  • Ringman JM, Cummings JL (2006) Current and emerging pharmacological treatment options for dementia. Behav Neurol 17: 5–16

    PubMed  Google Scholar 

  • Rogers J, Kirby LC, Hempelman SR etal (1993) Clinical trial of indomethacin in Alzheimer’s disease. Neurology 43: 1609–1611

    PubMed  CAS  Google Scholar 

  • Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT (1998) Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 46(Suppl 1): 7–12

    Article  PubMed  CAS  Google Scholar 

  • Rosler M, Anand R, Cicin-Sain A et al (1999) Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. Br Med J 318: 633–638

    CAS  Google Scholar 

  • Sano M, Ernesto C, Thomas RG et al (1997) A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 336: 1216–1222

    Article  PubMed  CAS  Google Scholar 

  • Sastre J, Lloret A, Borras C et al (2002) Ginkgo biloba extract EGb 761 protects against mitochondrial aging in the brain and in the liver. Cell Mol Biol (Noisy-le-grand) 48: 685–692

    CAS  Google Scholar 

  • Scharf S, Mander A, Ugoni A, Vajada F, Christophidis N (1999) A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 53(1): 197–201

    PubMed  CAS  Google Scholar 

  • Schenk D, Barbour R, Dunn W et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740): 173–177

    Article  PubMed  CAS  Google Scholar 

  • Schmidtke K, Hermeneit S (2007) High rate of conversion to Alzheimer’s disease in a cohort of amnestic MCI patients. Int Psychogeriatr (Epub ahead of print)

    Google Scholar 

  • Schneider LS, De Kosky ST, Farlow MR, Tariot PN, Hörr R, Kieser M (2005) A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2(5): 541–551

    Article  PubMed  CAS  Google Scholar 

  • Seabrook TJ, Jiang L, Thomas K, Lemere CA (2006) Boosting with intranasal dendrimeric Abeta 1–15 but not Abeta 1–15 peptide leads to an effective immune response following a single injection of Abeta 1–40/42 in APP-tg mice. J Neuroinflammation 5: 3–14

    Google Scholar 

  • Shumaker SA, Legault C, Rapp SR et al (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA 291(24): 2947–2958

    Article  PubMed  CAS  Google Scholar 

  • Siemers ER, Quinn JF, Kaye J et al (2006) Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66(4): 602–604

    Article  PubMed  CAS  Google Scholar 

  • Simons M, Schwätzler F, Lütjohann D et al (2002) Treatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 52: 346–350

    Article  PubMed  CAS  Google Scholar 

  • Simonsen AH, McGuire J, Hansson O et al (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64: 366–370

    Article  PubMed  Google Scholar 

  • Sinha S, Lieberburg I (1999) Cellular mechanisms of beta-amyloid production and secretion. Proc Natl Acad Sci USA 96: 11049–11053

    Article  PubMed  CAS  Google Scholar 

  • Sparks LD, Sabbagh MN, Connor DJ et al (2005) Atorvastatin for the treatment of mild to moderate Alzheimer disease — preliminary results. Arch Neurol 62: 753–757

    Article  PubMed  Google Scholar 

  • Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez, J, Browne P (2006) Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand 114(Suppl 185): 3–7

    Article  Google Scholar 

  • Tabet N, Feldman H (2002) Indomethacin for the treatment of Alzheimer’s disease patients. Cochrane Database Syst Rev 2: CD003673

    PubMed  Google Scholar 

  • Tabet N, Birks J, Grimley EJ (2000) Vitamin E for Alzheimer’s disease. Cochrane Database Syst Rev 4: CD002854

    PubMed  Google Scholar 

  • Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C (2000) A 5-month, randomized, placebo-controlled trial of galantamine In AD. The Galantamine USA-10 Study Group. Neurology 54: 2269–2278

    PubMed  CAS  Google Scholar 

  • Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317–371

    Article  PubMed  CAS  Google Scholar 

  • Tucker JM, Townsend DM (2005) Alpha-tocopherol: roles in prevention and therapy of human disease. Biomed Pharmacother 59(7): 380–387

    Article  PubMed  CAS  Google Scholar 

  • VFA (Verband Forschender Arzneimittelhersteller) (2004) Gutachten ”Defizite in der Arzneimittelverordnung in Deutschland“ für, von: Fricke & Pirke GmbH, 12.10.2004

    Google Scholar 

  • Villemagne VL, Ackermann U, Gong SJ (2005) A beta amyloid imaging in dementia with Lewy bodies and Alzheimer’s disease with 11c-PIB PET. J Nucl Med 46: 124P

    Google Scholar 

  • Weiser M, Rotmensch HH, Korczyn AD, Hartman R, Cicin-Sain A, Anand R; Rivastigmine-Risperidone Study Group (2002) A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral dis turbances. Int J Geriatr Psychiatry 17: 343–346

    Article  PubMed  Google Scholar 

  • Wilcock G, Howe I, Coles H, Lilienfeld S, Truyen L, Zhu Y, Bullock R and Members of the GAL-GBR-2 Study Group (2003) A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 20: 777–789

    Article  PubMed  CAS  Google Scholar 

  • Wilkinson DG, Passmore AP, Bullock R et al (2002) A multinational randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract 56: 441–446

    PubMed  CAS  Google Scholar 

  • Winblad B, Engedal K, Soininen H et al; Donepezil Nordic Study Group (2001) A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495

    PubMed  CAS  Google Scholar 

  • Winblad B, Cummings J, Andreasen N et al (2007) A six-month doubleblind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease — rivastigmine patch versus capsule. Int J Geriatr Psychiatry 22(5): 456–467

    Article  PubMed  Google Scholar 

  • Woodruff-Pak DS, Vogel RW 3rd, Wenk GL (2001) Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci USA 98: 2089–2094

    Article  PubMed  CAS  Google Scholar 

  • Yao Z, Drieu K, Papadopoulos V (2001) The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloidderived diffusible neurotoxic ligands. Brain Res 889: 181–190

    Article  PubMed  CAS  Google Scholar 

  • Zandi PP, Anthony JC, Khatchaturian AS et al for the Cache County Study Group (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements. Arch Neurol 61: 82–88

    Article  PubMed  Google Scholar 

  • Zhao X, Marszalec W, Toth PT, Huang J, Yeh JZ, Narahashi T (2006) In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 51: 1181–1191

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Isabella Heuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ion-George Anghelescu
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Max-Planck-Institut für Psychiatrie, Kraepelinstraße 2-10, 80804, München

    Florian Holsboer

  2. Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen, Pauwelsstraße 30, 52074, Aachen

    Gerhard Gründer

  3. Ehemals: Psychiatrische Klinik und Poliklinik der Johannes-Gutenberg-Universität Mainz, Untere Zahlbacher Straße 8, 55131, Mainz

    Otto Benkert

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Heuser, I., Anghelescu, IG. (2008). Antidementiva. In: Holsboer, F., Gründer, G., Benkert, O. (eds) Handbuch der Psychopharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68748-1_32

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68748-1_32

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-20475-6

  • Online ISBN: 978-3-540-68748-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation